King’s Doctoral Training Centre to investigate MS symptom management
Impacting more than 150,000 people in the UK, the lifelong autoimmune disease affects the brain and spinal cord
Read More
Tag: multiple sclerosis
100th patient joins ChariotMS trial for multiple sclerosis
The trial is testing whether Mavenclad could benefit upper limb movement in MS patients
Read More
Fewer MS patients are prescribed DMTs in UK compared to Europe
The study analysed and compared information from 65,000 MS patients
Read More
Sandoz’s Tyruko biosimilar granted FDA approval to treat relapsing MS
The disease-modifying therapy is approved to treat all indications covered by Tysabri
Read More
Sanofi announces positive data for frexalimab in relapsing MS
The neurological disease affects approximately 2.8 million people worldwide
Read More
MHRA authorises Vumerity for multiple sclerosis patients
Vumerity is a next-generation oral fumarate treatment for adults with relapsing-remitting multiple sclerosis
Read More
SMC accepts oral therapy for relapsing multiple sclerosis
Janssen’s Ponvory accepted for use within NHS Scotland for adults RRMS patients
Read More
Sanofi’s BTK inhibitor tolebrutinib shows ‘promising’ long-term MS data
Tolebrutinib reduced multiple sclerosis (MS) disease activity as measured by MRI
Read More
MHRA nod for Janssen’s relapsing multiple sclerosis drug Ponvory
Phase III trial showed a reduction in annual relapse rate
Read More
Novartis reveals long-term results for MS therapy Kesimpta
B-cell targeting therapy preserved patients’ IgG/IgM levels, with no increased risk of serious infections
Read More
EC approves Sanofi’s Aubagio for paediatric MS patients
Aubagio has been authorised for the treatment of paediatric patients aged ten to 17 years living with RRMS
Read More
EC approves Ponvory for relapsing MS
European approval follows the recent announcement of the FDA approval of Ponvory for RMS
Read More
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
